D.E. Shaw & Co
VTGN icon

D.E. Shaw & Co’s VistaGen Therapeutics VTGN Stock Holding History

D.E. Shaw & Co’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-442
Closed -$12K – 5560
2022
Q2 		$12K Sell
442
-8,658
-95% -$306K ﹤0.01% 5109
2022
Q1 		$339K Buy
9,100
+8,653
+1,936% +$377K ﹤0.01% 4589
2021
Q4 		$26K Sell
447
-2,986
-87% -$194K ﹤0.01% 5279
2021
Q3 		$282K Sell
3,433
-1,392
-29% -$121K ﹤0.01% 4397
2021
Q2 		$456K Buy
+4,825
New +$357K ﹤0.01% 4084

Other funds holding VTGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

D.E. Shaw & Co's VTGN Position: Q3 2022 in Review

D.E. Shaw & Co sold out of VistaGen Therapeutics (VTGN) in Q3 2022, closing a stake of 442 shares — an estimated $12K sold.

D.E. Shaw & Co first reported a position in VTGN in Q2 2021 and held it in 5 quarters. The position peaked at $456K in Q2 2021. 92 funds tracked by Wall St. Rank hold VTGN as of Q3 2022.

  • D.E. Shaw & Co reported no remaining VistaGen Therapeutics position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 442 VistaGen Therapeutics shares in Q3 2022, an estimated $12K.
  • D.E. Shaw & Co first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 5 quarters.
  • D.E. Shaw & Co's VistaGen Therapeutics position peaked at $456K in Q2 2021.
  • 92 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.